The Epidemiology and Diagnosis of Insomniania directly (and often prophylactically). Onthe other hand, chronic insomnia may bemore often related to intrinsic sleep disorders,primary insomnia, or chronic medicaland psychiatric conditions, and may requirea more extensive evaluation (includingassessment of <strong>com</strong>orbid conditions) in orderto delineate appropriate treatment. However,it should be stressed that the relationshipsbetween insomnia duration, etiology,and evaluation implications have not beenwell investigated.Insomnia can also be classified on thebasis of etiology into primary and secondarysubtypes. The term primary indicates thatthe insomnia is not caused by any knownphysical or mental condition but is characterizedby a consistent set of symptoms, adefined disease course, and a generalresponsiveness to treatment. 16,17 Althoughthe etiology of primary insomnia has yet tobe clarified, recent research implicatesendocrine, neurologic, and behavioral factorsas contributing to its pathogenesis. 18-20It is estimated that among patients diagnosedwith insomnia, 25% to 30% suffer fromprimary insomnia. 6,21 Secondary insomnia,in contrast, has been defined historically asinsomnia resulting from other medical andpsychiatric illnesses, medication use, orother primary sleep disorders. 5,22 The 2005NIH State-of-the-Science statement, however,has suggested the use of the term<strong>com</strong>orbid insomnia, instead of secondaryinsomnia, based on a limited level of understandingof the causal relationships whichmay exist between insomnia and coexistingdisorders. Conceivably, primary insomniacould coexist as an independent entity inthe context of another disorder, as opposedto being caused by it. 5Epidemiology and Natural Historyof InsomniaEstimates of the prevalence of insomniaare variable because definitions and diagnosticcriteria for insomnia are inconsistent. Inaddition, the use of baseline and follow-upassessments to establish incidence and remissionrates can be problematic because ofthe wide spectrum of insomnia duration (eg,a positive finding of insomnia at baselineand 1-year follow-up may reflect unremittingchronic insomnia or 2 episodes of transientinsomnia). 23 Given these limitations, itis generally believed that 10% to 15% ofadults suffer from chronic insomnia, 24 usuallyregarded as a persistent insomnia lastingmore than 1 month, and an additionalone third have transient or occasionalinsomnia. 25The elderly in particular are affected,with an estimated prevalence ranging from13% to 47%. 22,26-31 The National Institute onAging’s Established Populations for EpidemiologicStudies of the Elderly (EPESE) 3-yearlongitudinal study showed that 42% of <strong>com</strong>munity-dwellingseniors who participated inthe survey had difficulty falling and stayingasleep. 26,32 Sleep difficulties were moreprevalent among seniors with physical disability,depressed mood, respiratory symptoms,or fair-to-poor perceived health andamong those using anxiolytic and barbiturateprescription medication. At the 3-yearfollow-up of EPESE, Foley et al estimatedincidence and remission rates for insomniain more than 6000 participants of the originalsurvey. 32 Among 4956 participants whohad no symptoms of insomnia at baseline,nearly 15% reported symptoms at the 3-year follow-up, suggesting an annual incidenceof 5%.In the same study, for about 15% of participants,insomnia symptoms resolved eachyear. Extrapolating these findings to the generalpopulation, the authors estimated that8 million elderly persons nationwide haveinsomnia on any given day, more than 1 millionnew cases of insomnia develop eachyear, and symptoms resolve in nearly 1.3million elderly persons annually. 32 Disturbedsleep is also associated with impairmentsin memory and attention, and can bemisinterpreted as signs of dementia in theelderly. 33Although most epidemiologic studiesindicate that women are more likely to havesleep difficulties than men, 27,34 the EPESEstudy reported <strong>com</strong>parable rates in bothsexes. The exception to this parity occurredin patients 85 years or older, in which theprevalence was higher among men. 32 TheEPESE study also showed that women wereless likely to achieve remission (46% ofwomen vs 52% of men), suggesting the high-VOL. 12, NO. 8, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S215
REPORTSer prevalence in women reported in other epidemiologicstudies may indicate fewer remissionsin women, not more new cases. 32 Thishypothesis was supported by findings fromthe Cardiovascular Health Study of 2005,which reported that women with insomniawere less likely than men to remit. 35In addition to the EPESE study of elderlypatients, several other longitudinal studieshave helped clarify the natural history ofchronic insomnia. Breslau et al conducted abaseline assessment and 3.5-year follow-upof 1200 young adults (aged 21-30 years)drawn randomly from a health maintenanceorganization database. The lifetime prevalenceof insomnia in this population was24.6% and was slightly higher in women thanmen (26.7% and 21.4%, respectively). The3.5-year incidence of new insomnia amongsubjects with no insomnia at baseline was14.8% for women and 10.6% for men; slightlyless than the incidence rates reported inthe EPESE study. 36In a study of 521 healthy middle-agedwomen near menopause presenting at a clinic,Owens and Matthews found a very highprevalence (42%) of self-reported sleep difficulties.Among those reporting sleep problems,the most prevalent <strong>com</strong>plaint wasawakening during the night (reported by92%), followed by earlier-than-desired awakening(59%) and trouble falling asleep (49%).A cross-sectional analysis failed to identifysignificant associations between pre-, peri-,or postmenopausal status and general orspecific sleep <strong>com</strong>plaints. However, amongthe subset of women who were premenopausalat baseline and postmenopausal andnot using hormone replacement therapy atfollow-up, a higher proportion reported sleepdifficulties at the postmenopausal than atthe premenopausal assessment. 37Hohagen et al conducted a study of 2512patients aged 18 to 65 years presenting toprimary care clinics in Germany; a baselineassessment identified 18.7% with severeinsomnia (DSM-III-R criteria), 12.2% withmoderate insomnia (DSM-III-R criteria,without impairment of daytime functioning),and 15% with mild insomnia (occasionaldifficulties in initiating and maintainingsleep). Follow-up assessments were conductedin patients reporting baseline insomnia at4 months and 2 years. At baseline, mildinsomnia was more prevalent among men,but severe insomnia was more <strong>com</strong>monamong women by a nearly 2:1 margin (65%vs 35%). More than two thirds of patientswith severe insomnia at baseline reported adisease duration of 1 year or more. 38At the 4-month follow-up, 75% of thosereporting severe insomnia at baseline stillreported severe or moderate insomnia, withthe remainder reporting either mild symptomsor no symptoms. At 2 years, the persistenceof severe or moderate insomnia was52% among those with severe insomnia atbaseline; 42% of these patients reportedsevere insomnia at all 3 visits. 38 Importantly,despite the overall persistence of sleep <strong>com</strong>plaintsamong those with severe insomnia, afollow-up study revealed that the symptomaticpresentation shifted significantly overtime. For example, only half of those reportingexclusively sleep-onset difficulties atbaseline did so at 4 months, and the persistencyof sleep maintenance and early-awakening<strong>com</strong>plaints was even lower. Thissymptomatic lability calls into doubt theutility of insomnia classifications based ontime of night affected, at least among patientswith severe insomnia. 39Clinical Correlates of InsomniaThe longitudinal studies described abovehave also provided insight into the clinicalconditions <strong>com</strong>monly associated withinsomnia. Among young adults, prevalentinsomnia was associated most strongly withmajor depressive disorder (MDD), with anodds ratio (OR) for the presence of MDD of16.6 among subjects with insomnia <strong>com</strong>paredwith those without insomnia; the ORwas even higher (41.8) among subjectsreporting both insomnia and hypersomnia.A number of other psychiatric conditions,including anxiety disorders (ORs, 2.4-7.0),substance abuse disorders (OR, ~2 for bothalcohol and illicit substances), and nicotinedependence (OR, 2.8), were also highly correlatedwith insomnia. 36With regard to temporal patterns, a previoushistory of insomnia at baseline wasstrongly associated with the incidence ofnew psychiatric disorders, including MDD,anxiety disorders, substance abuse disorder,S216 THE AMERICAN JOURNAL OF MANAGED CARE MAY 2006
- Page 1 and 2:
Practice Management Tips ForSHIFT W
- Page 3 and 4:
Patient QuestionnaireDo you often f
- Page 5 and 6:
Sleep/Wake LogIn bedOut of bedLight
- Page 7 and 8:
PHQ-9 QUICK DEPRESSION ASSESSMENTFo
- Page 9 and 10:
Insomnia Severity IndexPlease answe
- Page 11 and 12:
Take-Away PointsSHIFT WORK DISORDER
- Page 13 and 14:
SHIFT WORKDISORDERBright Light Ther
- Page 40 and 41:
PrimarycareScreeningfor depressioni
- Page 42 and 43:
PrimarycareThescreening questionnai
- Page 44 and 45:
Shift-work disorderContents and Fac
- Page 46 and 47:
Shift-work disorderThe diagnosis of
- Page 48 and 49: Shift-work disorderas heightened le
- Page 50 and 51: Shift-work disorderFigure 1 Risk ra
- Page 52 and 53: Shift-work disorderare not function
- Page 54 and 55: The characterization andpathology o
- Page 56 and 57: Shift-work disorderFigure 2 Sleep/w
- Page 58 and 59: Shift-work disorderFigure 3 Blood p
- Page 60 and 61: Recognition of shift-workdisorder i
- Page 62 and 63: Shift-work disorderThe timing of sh
- Page 64 and 65: Shift-work disorderthe other potent
- Page 66 and 67: Managing the patient withshift-work
- Page 68 and 69: Shift-work disorderFigure 3 Optimal
- Page 70 and 71: Shift-work disorderfor a motor vehi
- Page 72 and 73: Shift-work disordermoderate caffein
- Page 74 and 75: Supplement toAvailable at jfponline
- Page 76 and 77: Armodafinil for Treatment of Excess
- Page 78 and 79: Armodafinil for Treatment of Excess
- Page 80 and 81: Armodafinil for Treatment of Excess
- Page 82 and 83: Armodafinil for Treatment of Excess
- Page 84 and 85: Armodafinil for Treatment of Excess
- Page 86 and 87: Armodafinil for Treatment of Excess
- Page 88 and 89: Armodafinil for Treatment of Excess
- Page 90 and 91: Armodafinil for Treatment of Excess
- Page 92 and 93: Armodafinil for Treatment of Excess
- Page 94 and 95: Armodafinil for Treatment of Excess
- Page 96 and 97: Armodafinil for Treatment of Excess
- Page 100 and 101: The Epidemiology and Diagnosis of I
- Page 102 and 103: The Epidemiology and Diagnosis of I
- Page 120 and 121: CIRCADIAN RHYTHM SLEEP DISORDERSPra
- Page 122 and 123: Table 2— AASM Levels of Recommend
- Page 124 and 125: 3.2.1.1 Both the Morningness-Evenin
- Page 126 and 127: Five studies used one of the newer
- Page 128 and 129: as an indicator of phase in sighted
- Page 130 and 131: 4.4 Advanced Sleep Phase DisorderBe
- Page 132 and 133: 45. Walsh, JK, Randazzo, AC, Stone,
- Page 134: 123. Van Someren, EJ, Kessler, A, M
- Page 142 and 143: Table 1—Subject Demographicsn M:F
- Page 144 and 145: Scale. 28 The simple reaction time
- Page 146 and 147: Median RT (msec)1600A14001200100080
- Page 148 and 149:
10Mentally AExhaustedSharpScore8642
- Page 150 and 151:
Current Treatment Options in Neurol
- Page 152 and 153:
398 Sleep Disordersand sleep loss,
- Page 154 and 155:
400 Sleep DisordersTable 1. Treatme
- Page 156 and 157:
402 Sleep DisordersStandard dosageC
- Page 158 and 159:
404 Sleep DisordersStandard procedu
- Page 160 and 161:
406 Sleep DisordersCaffeineMelatoni
- Page 162 and 163:
408 Sleep DisordersWake-promoting a
- Page 164 and 165:
410 Sleep Disordersnight shift: ada